Physician profile
Faria Ali
NPI 1225565666
$2,527.53
in general payments reported to CMS, 2019-2025
49 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.80 · 2020: $77.03 · 2021: $99.00 · 2023: $395 · 2024: $922 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $148.19 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Novocure INC. | $146.81 | 2024 | Optune |
| Novartis Pharmaceuticals Corporation | $145.71 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $140.09 | 2023-2024 | Rezlidhia, Tavalisse |
| Gilead Sciences, INC. | $121.29 | 2020-2024 | |
| Celgene Corporation | $114.03 | 2023-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $106.93 | 2024-2025 | Keytruda, Keytruda Qlex |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 | |
| Daiichi Sankyo INC. | $92.62 | 2023-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $91.93 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Aveo Pharmaceuticals, INC. | $78.44 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $77.51 | 2025 | Libtayo |
| Lilly USA, LLC | $77.01 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $72.47 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $55.13 | 2024-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $54.09 | 2023 | Intellis Adaptivestim |
| Tersera Therapeutics LLC | $53.73 | 2025 | Xermelo, Zoladex |
| Taiho Oncology, INC. | $51.03 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $46.26 | 2025 | Lynparza |
| Eisai INC. | $45.70 | 2023-2025 | |
| Incyte Corporation | $43.70 | 2024-2025 | Zynyz, Niktimvo, Monjuvi |
| Pharmaessentia USA Corporation | $40.10 | 2024-2025 | Besremi |
| Array Biopharma INC | $37.75 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Genentech USA, INC. | $36.57 | 2025 | Venclexta |
| Legend Biotech USA INC. | $34.42 | 2025 | Carvykti |
| Abbvie INC. | $32.92 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.57 | 2024 | Fruzaqla |
| Deciphera Pharmaceuticals INC. | $28.08 | 2024 | Qinlock |
| Tempus Ai, INC | $27.70 | 2025 | Xt Cdx |
| Acrotech Biopharma INC. | $27.30 | 2024 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.77 | 2024 | Gilotrif |
| Genmab U.S., INC. | $23.06 | 2024 | Tivdak |
| Beone Medicines USA, INC. | $22.81 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $22.76 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.16 | 2024 | Givlaari |
| Stemline Therapeutics INC. | $22.10 | 2025 | Orserdu |
| Karyopharm Therapeutics INC. | $21.09 | 2024 | Xpovio |
| Caris Mpi, INC. | $20.72 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $20.45 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.35 | 2024 | Somatuline Depot, Onivyde |
| Geron Corporation | $20.35 | 2025 | Rytelo |
| Genzyme Corporation | $19.54 | 2024 | |
| Adc Therapeutics America, INC. | $18.04 | 2023 | |
| Astellas Pharma US INC | $17.89 | 2025 | Vyloy |
| Alexion Pharmaceuticals, INC. | $16.38 | 2024 | Ultomiris |
| Springworks Therapeutics, INC. | $15.79 | 2024 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $15.07 | 2025 | Danziten |
| Glaxosmithkline, LLC. | $14.32 | 2025 | Ojjaara |
| Amgen INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faria Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.